Latest Fundraising News

Sentinel Metals has locked in a $15 million institutional placement to fund its acquisition of the 1.01Moz Big Springs Gold Project in Nevada, positioning itself as a growing North American gold player.

Papyrus Australia reached a key production milestone by delivering 200 biodegradable Collar Keeper® samples to TBS Mining Solutions, confirming its manufacturing scalability. The company’s May cash flow shows a steady funding runway amid ongoing R&D and commercialisation efforts.

Canadian Phosphate (ASX: CP8) secured $5.2 million through a rights issue and follow-on placement, positioning itself to accelerate exploration and development across key projects in Canada and the US.

Racura Oncology has raised $34.3 million through shareholder-backed initiatives, securing funding for its lead asset RC220’s clinical trials in AML, EGFRm lung cancer, and cardioprotection in solid tumour patients.

TZ Limited (ASX:TZL) is raising $3.08 million through a $0.50 million placement and a $2.58 million entitlement offer at 3 cents per share to repay debt, fund acquisitions, and accelerate product development.

Racura Oncology has secured $31.2 million in funding to advance its lead cancer drug RC220, including a strategic $1 million private placement to a specialist healthcare investor.

Dome Gold Mines (ASX:DME) is raising up to AUD 2 million through unsecured convertible notes to fast-track its Sigatoka feasibility study, mining lease application, and copper-gold exploration amid rising metal prices.

Dotz Nano has pushed out the maturity dates on its convertible notes to March 2027, securing continued backing from Mercer Street Capital. The move introduces new conversion limits and an option for cash settlements, signalling confidence in Dotz’s carbon capture ambitions.

Excite Technology Services lifted revenue by 74% to $21.3 million in FY26 but still recorded a $5.4 million loss, with auditors flagging material uncertainty over its ability to continue as a going concern.

Atomo Diagnostics has closed a modest Share Purchase Plan, raising $44,500 and issuing free attaching options, while reserving a substantial shortfall for future placement.

Vectus Biosystems appoints Dr Tara Speranza as CEO and CTO to accelerate development of lead fibrosis drug VB0004 with performance-linked incentives.

The GPT Group delivered strong operational results in Q1 2026 with near-record occupancy across retail, office, and logistics assets, alongside solid retail sales and leasing activity. The group’s $610 million oversubscribed equity raise in its Wholesale Shopping Centre Fund underpins growth plans, while FY 2026 earnings guidance is reiterated.